Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Anticoagulants

Genotype-guided dosing improves safety of warfarin

Older adults who received a genotype-guided dose of warfarin via a web application were less likely to experience adverse effects compared with clinical dosing, trial results show.

Screen shot of the warfarin dosing web application

Source: warfarindosing.org

Patients were randomised to receive either clinical dosing or genotype-guided dosing via the web application www.warfarindosing.org 

Warfarin is widely prescribed to prevent blood clots that can cause stroke or deep vein thrombosis. However, finding the optimum dose is a challenge and patients need regular monitoring.

Researchers conducted a randomised controlled trial with 1,597 patients aged 65 years or older who were initiating warfarin prior to elective hip or knee replacement. The patients were genotyped for four different polymorphisms that influence warfarin sensitivity, metabolism and vitamin K recycling (CYP2C9*2, CYP2C9*3; VKORC1-1639G>A; and CYP4G2 V433M respectively).

Patients were randomised to receive either clinical dosing or genotype-guided dosing via a web application (www.warfarindosing.org). After 11 days, participants could continue with the dose or make adjustments.

At 30-day follow-up, the researchers found that the rate of adverse events was 14.7% in the clinical arm and 10.8% in the genotype-guided arm, a relative risk reduction of 27.0%.

Presenting at the American College of Cardiology’s 66th Annual Scientific Session on 19 March 2017 in Washington DC, the researchers said their findings provide evidence that genotype-guided dosing improves the safety of warfarin.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20202512

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Screen shot of the warfarin dosing web application

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.